1-20 of 396
Alessandra Ferrajoli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger
Journal: Blood
Blood blood.2024025683.
https://doi.org/10.1182/blood.2024025683
Published: 2024
Includes: Supplemental data
Journal Articles

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Clinical Trials & Observations
Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, M.D., Constantine S. Tam, Lugui Qiu, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter Stephen Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Prof., Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood blood.2024024667.
https://doi.org/10.1182/blood.2024024667
Published: 2024
Includes: Supplemental data
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Nitin Jain, Philip Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati, Koichi Takahashi, Mahesh Swaminathan, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan M. Kadia, Naveen Pemmaraju, Koji Sasaki, Divyam Bansal, Marina Y. Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Wei Wang, Sa A. Wang, Jeffrey L. Jorgensen, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M. Kantarjian, Susan M. O'Brien, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3267.
https://doi.org/10.1182/blood-2023-188084
Published: 2023
Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Ivo Veletic, David M. Harris, Uri Rozovski, Ping Li, Zhiming Liu, Taghi Manshouri, Maria Teresa S. Bertilaccio, George A. Calin, Rares-Constantin Drula, Koichi Takahashi, Ken Furudate, Muharrem Muftuoglu, Anwar Hossain, Alessandra Ferrajoli, Jan A. Burger, Nitin Jain, William G. Wierda, Srdan Verstovsek, Michael J. Keating, Zeev Estrov
Journal: Blood
Blood (2023) 142 (Supplement 1): 3264.
https://doi.org/10.1182/blood-2023-190712
Published: 2023
Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Jan A. Burger, Ekaterina Kim, Mariela Sivina, Thomas Mathew, Danielle E. Hammond, Fadi G. Haddad, Alessandra Ferrajoli, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 6524.
https://doi.org/10.1182/blood-2023-178774
Published: 2023
Journal Articles

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Guilin Tang, Fadi G. Haddad, Nitin Jain, Ghayas C. Issa, Tapan M. Kadia, Naval Daver, Alessandra Ferrajoli, Monica Kwari, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Patrice Eric Nasnas, Naveen Pemmaraju, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 1500.
https://doi.org/10.1182/blood-2023-181379
Published: 2023
Journal Articles

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

Alexandre Bazinet, Hagop M. Kantarjian, Gautam Borthakur, Musa Yilmaz, Prithviraj Bose, Elias Jabbour, Yesid Alvarado Valero, Kelly S. Chien, Naveen Pemmaraju, Koichi Takahashi, Nicholas J. Short, Naval Daver, Ghayas C. Issa, Nitin Jain, Danielle E. Hammond, Debra Bull-Linderman, Courtney D. DiNardo, Jan A. Burger, Alessandra Ferrajoli, Guillermo Montalban-Bravo, Koji Sasaki, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2023) 142 (Supplement 1): 2884.
https://doi.org/10.1182/blood-2023-172882
Published: 2023
Journal Articles

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 202.
https://doi.org/10.1182/blood-2023-174289
Published: 2023
Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Himachandana Atluri, Jillian Mullin, Koichi Takahashi, Sanam Loghavi, Abhishek Maiti, Koji Sasaki, Naval Daver, Yesid Alvarado Valero, Naveen Pemmaraju, Gautam Borthakur, Danielle E. Hammond, Kelly S. Chien, Alessandra Ferrajoli, Nicholas J. Short, Hussein A Abbas, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Rebecca S.S. Tidwell, Xuemei Wang, Marina Y. Konopleva, Guillermo Garcia-Manero, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood
Blood (2023) 142 (Supplement 1): 968.
https://doi.org/10.1182/blood-2023-182944
Published: 2023
Journal Articles

Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL)

Jayastu Senapati, Hagop M. Kantarjian, Elias Jabbour, Rodrick Babakhanlou, Tapan M. Kadia, Gautam Borthakur, Marina Y. Konopleva, William G. Wierda, Jan A. Burger, Ghayas C. Issa, Abhishek Maiti, Hayley S. Balkin, Mary Kelly, Rebecca Garris, Alessandra Ferrajoli, Guillermo Garcia-Manero, Yesid Alvarado Valero, Partow Kebriaei, Nicholas J. Short, Nitin Jain, Farhad Ravandi
Journal: Blood
Blood (2023) 142 (Supplement 1): 963.
https://doi.org/10.1182/blood-2023-179562
Published: 2023
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Mahesh Swaminathan, Koichi Takahashi, Zeev Estrov, Marina Y. Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado Valero, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A. Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 4635.
https://doi.org/10.1182/blood-2023-189711
Published: 2023
Journal Articles

Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib

Alessandra Ferrajoli, George Follows, Yotvat Marmor, Shogheeg Apkarian Bourjlian, Jack Roos, Naghmana Bajwa, Venkata Madhira, Kenji Nozaki, Paulo Andre P. Palhares De Miranda, Krish Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1917.
https://doi.org/10.1182/blood-2023-174727
Published: 2023
Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, Krish Patel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia A. Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, John C. Byrd, Emmanuelle Ferrant, Alessandra Ferrajoli, William G. Wierda, Veerendra Munugalavadla, Catherine Wangui Wachira, Chuan-Chuan Wun, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 636.
https://doi.org/10.1182/blood-2023-174750
Published: 2023
Journal Articles

Elevate-TN: Impact of First-Year Dose Modifications in Patients with Treatment-Naive Chronic Lymphocytic Leukemia Treated with Acalabrutinib

George Follows, Alessandra Ferrajoli, John C. Byrd, Bob Shaw, Kenji Nozaki, Katherine Stewart, Paulo Andre P. Palhares De Miranda, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 4645.
https://doi.org/10.1182/blood-2023-174767
Published: 2023
Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Musa Yilmaz, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado Valero, Abhishek Maiti, Cedric Nasnas, Lewis Nasr, Rebecca Garris, Marina Y. Konopleva, Farhad Ravandi, Elias Jabbour
Journal: Blood
Blood (2023) 142 (Supplement 1): 4245.
https://doi.org/10.1182/blood-2023-190902
Published: 2023
Journal Articles

Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis

Alejandro Marinos Velarde, Rima M. Saliba, Celina Ledesma, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Uday R. Popat, Qaiser Bashir, Yago Nieto, David Marin, Betul Oran, Amanda L. Olson, Samer A. Srour, Amin Alousi, Jeremy Ramdial, Partow Kebriaei, Alessandra Ferrajoli, William G. Wierda, Richard E. Champlin, Chitra Hosing
Journal: Blood
Blood (2023) 142 (Supplement 1): 7086.
https://doi.org/10.1182/blood-2023-173194
Published: 2023
Journal Articles

NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis

Hila Shaim, Hind Rafei, Mecit Kaplan, Rafet Basar, May Daher, MD, Mayra Shanley, Pinaki Banerjee, Bijender Kumar, Ana K. Nunez Cortes, Sanjida Islam, Xin Ru Jiang, Lucila Nassif Kerbauy, Paul Lin, Elif Gokdemir, Nadima Uprety, Sunil Acharya, Mayela Carolina Mendt, Luciana Melo Garcia, Alexander Biederstädt, Bin Liu, Enli Liu, Sonny Ang, Jan A. Burger, William G. Wierda, Alessandra Ferrajoli, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1895.
https://doi.org/10.1182/blood-2023-189671
Published: 2023
Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Megan (Der Yu) Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2022-171538
Published: 2022
Journal Articles

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Nicholas Short, Elias Jabbour, Farhad Ravandi, Musa Yilmaz, Tapan M. Kadia, Philip A. Thompson, Xuelin Huang, Marina Konopleva, Alessandra Ferrajoli, Nitin Jain, Koji Sasaki, Walid Macaron, Yesid Alvarado, Gautam Borthakur, Courtney D. DiNardo, Maro Ohanian, Steven M. Kornblau, Min Zhao, Monica Kwari, Jennifer Thankachan, Christopher Loiselle, Ricardo Delumpa, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 8966–8968.
https://doi.org/10.1182/blood-2022-157358
Published: 2022
Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

Himachandana Atluri, Abhishek Maiti, Koji Sasaki, Naval Daver, Yesid Alvarado, Md Feroz Hossain, Xuemei Wang, Naveen Pemmaraju, Koichi Takahashi, Gautam Borthakur, Alessandra Ferrajoli, Nicholas Short, Hussein A Abbas, Farhad Ravandi, Elias Jabbour, Michael Andreeff, Guillermo Garcia-Manero, Hagop Kantarjian, Marina Konopleva, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 6170–6172.
https://doi.org/10.1182/blood-2022-164986
Published: 2022